Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
MarketWatch
First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from MarketWatch.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
MarketWatch (www.marketwatch.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 67.9 of 100 in the snapshot this page was rendered from.
- Freshness
- 29.9 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 10 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Business · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Wall Street (3), Novo Nordisk (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.